Compliance and persistence with osteoporosis therapies

Current Rheumatology Reports

Volumn 10, Issue 2, 2008, Pages 118-122

  Silverman, Stuart L ^a   Gold, Deborah T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

COPING BEHAVIOR; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; EDUCATIONAL STATUS; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; RACE DIFFERENCE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEX DIFFERENCE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOPOROSIS; PATIENT COMPLIANCE; RHEUMATIC DISEASES;

EID: 44949171731     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0021-x     Document Type: Review

References (30)

1. World Health Organization: Adherence to long-term therapies: evidence for action. Available at http://www.emro.who.int/ncd/Publications/ adherence_report.pdf. Accessed February 8, 2008.
2. Cramer JA, Roy A, Burrell A, et al.: Medication compliance and persistence: terminology and definitions. Available at http://www.ispor.org/sigs/medcompliance/ medicationcomplianceandpersistence.asp. Accessed February 8, 2008.
3. Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856-861.
4. Sunyecz J, Gallagher R, MacCosbe P: Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female Patient 2006, 31:21-28.
5. Ettinger M, Gallagher R, MacCosbe P: Medication persistence with weekly vs. daily doses of oral bisphosphonates. Endocr Pract 2006, 12:522-528.
6. Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
7. Brankin E, Walker M, Lynch N, et al.: The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006, 22:1249-1258.
8. Cramer JA, Lynch NO, Gaudin AF, et al.: The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006, 28:1686-1694.
9. Silverman SL, Cramer JA, Sunyecz JA, et al.: Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12-month results from two retrospective databases [abstract W366]. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16-20, 2007.
10. Cooper A, Drake J, Brankin E; the PERSIST Investigators: Treatment persistence with once monthly ibandronate and patient support vs once weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006, 60:896-905.
11. Gold DT, Safi W, Trinh H: Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006, 22:2383-2391.
12. Weiss TW, Henderson SC, McHorney CA, Cramer JA: Persistence across weekly and monthly bisphosphonates: analysis of US retail prescription pharmacy refills. Curr Med Res Opin 2007, 23:2193-2203.
13. Cramer JA, Silverman SL, Gold DT: Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 2007, 23:2369-2377.
14. Curtis JR, Westfall A, Cheng H, et al.: Longitudinal patterns of adherence with bisphosphonates. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16-20, 2007.
15. Curtis JR, Westfall A, Allison JJ, et al.: Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006, 17:1268-1274.
16. Yood RA, Emani S, Reed JI, et al.: Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003, 14:965-968.
17. Silverman SL, Gold DT, Cramer JA: Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007, 100:1214-1218.
18. Siris ES, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures using 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022. [Comment in: Mayo Clin Proc 2006, 81:1009-1012.]
19. Caro JJ, Ishak KJ, Huybrechts KF, et al.: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
20. Weycker D, Macarios D, Edelsberg J, Oster G: Compliance with osteoporosis drug therapy and risk fracture. Osteoporos Int 2007, 18:271-277.
21. Kamatari M, Koto S, Ozawa N, et al.: Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 2007, 25:302-309.
22. Badamgarav E, Fitzpatrick LA: A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 2006, 81:1009-1012.
23. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J: Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48:271-287.
24. Gold DT, Martin BC, Frytak JR, et al.: A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007, 23:585-594.
25. Cramer JA, Gold DT, Silverman, SL, Lewiecki EM: A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023-1031.
26. de Klerk E, van der Heijde D, Landewe R, et al.: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003, 30:44-54. [Erratum in: J Rheumatol 2003, 30:423.]
27. Dominick KL, Golightly YM, Bosworth HB: Racial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritis. Ethn Dis 2005, 15:116-122.
28. Nived O, Andersson M, Lindgren M, et al.: Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. Lupus 2007, 16:701-706.
29. Eastell R: Management of bone health in postmenopausal women. Horm Res 2005, 64(Suppl 2):76-80.
30. Lewiecki M: Medications don't work if patients don't take them [editorial]. South Med J 2007, 100:1190-1191.